Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund C A, Mäkelä O
J Clin Pathol. 1984 Feb;37(2):218-22. doi: 10.1136/jcp.37.2.218.
Serum CA 19-9 antigen concentrations were measured in 246 patients with benign and histologically confirmed malignant gastrointestinal diseases. The CA 19-9 concentration was above the upper limit of the normal range (0-37 U/ml) in 76% of patients with pancreatic carcinoma, 73% of patients with cholangiocarcinoma, 42% of patients with gastric carcinoma, and 22% of patients with hepatoma. High CA 19-9 concentrations were found mainly in patients with a metastasised cancer, whereas 71% of patients with a localised carcinoma had normal CA 19-9 concentrations. All of the patients with benign gastric diseases had normal CA 19-9 values. Moderately increased concentrations were found in 15-36% of the patients with benign pancreatic, liver, and biliary tract diseases. alpha-fetoprotein was a better marker for hepatomas than CA 19-9. CA 19-9 was better than carcinoembryonic antigen in differentiating malignant from benign diseases. The results indicate that the CA 19-9 assay is not completely specific for cancer but serves as a valuable adjunct, especially in the diagnosis of pancreatic carcinoma.
对246例经组织学确诊的良性和恶性胃肠道疾病患者测定了血清CA 19-9抗原浓度。76%的胰腺癌患者、73%的胆管癌患者、42%的胃癌患者和22%的肝癌患者的CA 19-9浓度高于正常范围上限（0 - 37 U/ml）。高CA 19-9浓度主要见于癌症转移患者，而71%的局限性癌患者CA 19-9浓度正常。所有良性胃病患者的CA 19-9值均正常。15% - 36%的良性胰腺、肝脏和胆道疾病患者的CA 19-9浓度中度升高。甲胎蛋白对肝癌来说是比CA 19-9更好的标志物。在区分良性和恶性疾病方面，CA 19-9比癌胚抗原更好。结果表明，CA 19-9检测对癌症并非完全特异，但作为一种有价值的辅助手段，尤其在胰腺癌诊断中。
